ArticleBlood2012
Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Distinct Requirements for CD4European journal of immunology · 2025Article
- Review
- The role of CD4MedComm · 2023Review
- Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions.International journal of molecular sciences · 2021Review
- Differentiation and Regulation of TFrontiers in immunology · 2021Review
- Review
- CD4Nature reviews. Immunology · 2018Review
- Resident memory T cells, critical components in tumor immunology.Journal for immunotherapy of cancer · 2018Review
- Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
- Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act.Frontiers in immunology · 2018Review
- Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.Nature immunology · 2017Article
- The multifaceted role of CD4(+) T cells in CD8(+) T cell memory.Nature reviews. Immunology · 2016Review
- Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Pharmacology & therapeutics · 2015Review
- Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics.Human vaccines & immunotherapeutics · 2014Review
- Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.The Journal of clinical investigation · 2013Article
- T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.Critical reviews in immunology · 2013Review
- Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma.PloS one · 2013Article
- Trauma patients' elevated tumor necrosis related apoptosis inducing ligand (TRAIL) contributes to increased T cell apoptosis.Clinical immunology (Orlando, Fla.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
CD4(+) Th cells are pivotal for the generation and maintenance of CD8(+) T-cell responses. "Helped" CD8(+) T cells receive signals during priming that prevent the induction of the proapoptotic molecule TNF-related apoptosis-inducing ligand (TRAIL) during reactivation, thereby enabling robust secondary expansion. Conversely, "helpless" CD8(+) T cells primed in the absence of Th induce TRAIL expression after restimulation and undergo activation-induced cell death. In the present study, we investigated the molecular basis for the differential regulation of TRAIL in helped versus helpless CD8(+) T cells by comparing their transcriptional profiles, and have identified a transcriptional corepressor, NGFI-A binding protein 2 (Nab2), that is selectively induced in helped CD8(+) T cells. Enforced expression of Nab2 prevents TRAIL induction after restimulation of primary helpless CD8(+) T cells, and expression of a dominant-negative form of Nab2 in helped CD8(+) T cells impairs their secondary proliferative response that is reversible by TRAIL blockade. Finally, we observe that the CD8(+) T-cell autocrine growth factor IL-2 coordinately increases Nab2 expression and decreases TRAIL expression. These findings identify Nab2 as a mediator of Th-dependent CD8(+) T-cell memory responses through the regulation of TRAIL and the promotion of secondary expansion, and suggest a mechanism through which this operates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.